Introduction
RASopathies are a clinically defined group of medical genetic syndromes caused by germline mutations in the genes that encode components or regulators of the RAS/mitogen activated protein kinase (MAPK) pathway. Taken together, the RASopathies represent one of the most prevalent group of congenital malformation syndromes affecting approximately 1 in 1,000 individuals [
1].
The RAS/MAPK pathway is a ubiquitous, highly conserved, intracellular signaling pathway that is critical in the cell cycle regulation, differentiation, growth, apoptosis and cell senescence [
1]. Abnormalities in RAS expression, activation, and signaling pathways appear to play also an important role in the regulation of the inflammatory response and in autoimmune mechanisms [
2‐
5].
RASopathies group include: Noonan syndrome (NS) caused by mutations in
PTPN11, SOS1,
RAF1, KRAS, NRAS and CBL; NS-like with loose anagen hair (NSLAH) due to germline mutations of
SHOC2 [
6] or more rarely,
PPP1CB [
7]; NS with multiple lentigines (NSML) caused by specific mutations of
PTPN11 [
8], although other rare mutations have been reported [
9]; Costello syndrome (CS) caused by activating mutations in
HRAS; cardio-facio-cutaneous syndrome (CFC) caused by gain of function mutations in
BRAF and
MAP2K1 or
MAP2K2 [
1]. Heterozygous missense mutations in
MAP2K1 (
MEK1) and
MAP2K2 (
MEK2) are present in approximately 25% of CFC individuals [
10]. Mutations
RIT1 have been identified in 17 of 180 patients (9%) with Noonan syndrome or a related condition but with no detectable mutations in known Noonan-related genes [
11].
LZTR1 may be responsible of a rare percentage of NS cases [
1].
RASopathies are multisystemic disorders with a unique phenotype, but they share many overlapping characteristics, including craniofacial dysmorphism, cardiac malformations, cutaneous, musculoskeletal, and ocular abnormalities, neurocognitive impairment; hypotonia and an increased cancer risk [
12].
A RAS-associated autoimmune leukoproliferative disorder (RALD) has been described, characterized by a non-malignant clinical picture, partly overlapping to that of autoimmune lymphoproliferative syndrome (ALPS), represented by lymphadenopathy, splenomegaly, increased circulating B lymphocytes, hypergammaglobulinemia and autoimmunity. Unlike ALPS, RALDs do not generally show increased values of circulating double negative T lymphocytes, increased values of vitamin B12 or mutation of FAS, FASL or CASP10 [
13].
Autoimmune diseases have rarely been described in NS. Case reports of patients with NS and autoimmune diseases such as systemic lupus erythematosus, celiac disease, Hashimoto thyroiditis [
14] and chronic idiopathic thrombocytopenic purpura have been described [
15]. Few cases of NS associated with autoimmune hepatitis have also been reported [
16]. A cohort of patients with RASopathies including 42 patients showed a high frequency of positivity of autoantibody titers, in the presence or absence of associated clinical manifestations [
17].
The aim of the present study was to perform immunological evaluation in a group of patients affected by RASopathies.
Patients and methods
69 patients (43 males, 26 female) affected by RASopathy were enrolled in the study: 60 at the Pediatric Genetic Section of the University Federico II of Naples, 7 at the Department of Clinical and Experimental Medicine of the University Magna Graecia of Catanzaro and two at Department of Medicine, Surgery and Dentistry “Scuola Medica Salernitana”, Salerno (Italy). The protocol was discussed with each patient (or legal tutor) and informed consent was obtained.
Clinical diagnosis were: 61 NS, 5 CFC, 3 NSML. The mean age at the moment of the enrolment was 8.72 years, (ranges 0 to 26 years).
The enrollment was carried out according to the following inclusion criteria: (i) clinical diagnosis of RASopathy, based upon clinical features and confirmed by molecular analysis performed on DNA extracted from circulating leucocytes, (ii) informed consent expression. The exclusion criteria were: (i) denied consent to participate to the study.
The patients enrolled presented the following genetic mutations distribution: 56.52% PTPN11, 13.04% SOS1, 11.59% BRAF, 5.8% RIT1, 4.35% LZTR1, 2.9% RAF1, 1.45% KRAS, 1.45% MAP2K2, 1.45% MEK1.
50 age- and sex-matched healthy controls were also enrolled (30 males, 20 females) mean age 8.7 years (ranges 0–26).
This is a retrospective study: patients’ clinical data were obtained from medical records over the past 20 years. Moreover all patients (or legal tutor) underwent anamnestic recall, clinical examination, including auxological parameters. Clinical findings suggestive for infections disease or auto-immune disorder were recorded including: upper and lower airway infections, otitis, skin infection and/or presence of arthralgia, artritis, purpura. For all the categories, the type of defects and the frequency of the individual anomalies were analyzed. All autoimmune disorders were excluded or diagnosed in the study cohort according to international consensus criteria [
18‐
24]. In all patients complete blood count, determination of C-reactive protein and thyroid profile were performed.
In a group of 44/69 patients and 30/50 controls quantitative analysis of immunoglobulin levels (IgA, IgG, IgM, IgE), was performed and interpreted according to the normal range (± 2DS) proposed by Ugazio et al. [
25].
In a group of 35/69 patients and 50/50 controls CD3, CD4, CD8, CD19, CD56 lymphocyte subpopulations was performed by FACS and the normal range was considered according to the protocol provided by Dallavilla et al. [
26].
Patients sample (24/69) were screened for antinuclear antibodies (ANA) by ELISA. Dilutions 1:320 were defined as positive. Anti Tg, anti-TPO, anti r-TSH anti-and LKM1 antibodies were assayed by ELISA. ENA and anti-dsDNA were measured by chemiluminescence. Rheumatoid factor (RF), anti-double-stranded DNA (anti-dsDNA), Anti-smooth muscle antibodies, anticardiolipin, Lupus anticoagulant, Anti-neutrophil cytoplasm antibody (ANCA), anti Tgasi, anti-beta 2 glycoprotein 1, glutamic acid anti-decarboxylase (GAD), anti-insulin (IAA), anti-tyrosine phosphatase (IA-2A) and anti-zinc transporter 8 were also detected. The serum levels of the C3 and C4 complement components were determined.
In a group of 10/69 patients and 10/50 controls available for further blood sampling, screening of a panel of inflammatory molecules was performed including PDGF, IL-1b, IL-1ra, IL-2, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-12(p70), IL-13, IL-15, IL-17, Eotaxin, FGF basic, G-CSF, GM-CSF, IFN-g, IP-10, MCP-1(MCAF), MIP-1a, MIP-1b, RANTES, TNF-a, VEGF. The tested molecules were chosen because they are important players in the pathogenesis of autoimmune disease.
Statistical analysis
Each numerical variable is expressed as mean ± SD. Statistical analysis was performed using SPSS package.
Differences in the lymphocytes, autoantibodies and inflammatory molecules levels between patients and controls were analyzed using the t-test for unpaired data corrected for Fisher exact test. To investigate the presence of an association between severity of phenotype and either DNA mutation or specific gene involved, χ2 test was performed.
A P value < 0.05 was considered to be significant in all instances.
Discussion
Abnormalities of the immune system or autoimmune diseases are rarely reported in patients affected by RASopathies. The current retrospective study performed immunological investigation in a cohort of 69 patients and 50 controls.
The results of the current study showed lower IgA levels in patients than in controls with a prevalence of 18% of IgA deficiency in patients group. The worldwide prevalence of selective IgA deficiency depends on the ethnic background and it is most prevalent in Caucasians (1:600) [
27]. Most individuals are asymptomatic, but the defect may be associated with recurrent respiratory and gastrointestinal tract infections/disorders, autoimmunity and allergies [
28,
29]. Recurrent upper respiratory tract infections were recorded in patients with IgA deficiency in the current study. We suggest to investigate immunoglobulin serum levels in patients affected by RASopathies.
Recently, a cohort of 42 patients with RASopathies was evaluated for autoimmune status. Autoimmune antibodies were observed in 52% of the patients. Remarkably, three (7%) of the patients had specific gastrointestinal and liver autoantibodies without clinical findings. Six patients (14%) fulfilled the clinical criteria for autoimmune diseases [systemic lupus erythematous, polyendocrinopathy (autoimmune thyroiditis and celiac disease), primary antiphospholipid syndrome, autoimmune hepatitis, vitiligo, and autoimmune thyroiditis] [
17]. Other cases of autoimmune diseases are reported anecdotally in patients with Rasopathies [
2,
30‐
33].
Although clinical findings suggestive for autoimmune disease were detected in only one patient of the current case load, biochemical parameters showed specific alterations.
Our study has highlighted the frequent finding of thyroid autoantibodies (25%), all in condition of euthyroidism, as already reported [
34]. In recent years, numerous prospective studies have demonstrated that many autoantibodies can be detected in the serum of asymptomatic or paucisymptomatic individuals who later develop an autoimmune disease. These antibodies can therefore precede the clinical symptoms of the disease by years, and could in principle be used for diagnostic and prognostic purposes, including screening studies [
35].
Reduced CD8+ T-cells levels were also demonstrated in our patients. Although the role of CD8+ T cells is not as well established, it is known that CD8+ T cells contribute to the induction, progression, pathogenesis and protection from many autoimmune diseases [
36‐
38].
As known, Ras/MAPK signalling is also implicated in peripheral tolerance to prevent autoimmune destruction by self-reactive T cells that escape thymic deletion. In particular, Erk MAPK pathway plays a critical role in CD8 T cell activation, proliferation, and survival [
39].
On the basis of data reported in literature, it might be suggested that impairment of RAS-MAPK pathway alters CD8 production causing intolerance and cross reactivity. Other studies are needed to confirm these hypotheses.
We hypothesized that reduced CD8+ T-cells levels might be the first detectable sign of possible emergence of autoimmune disease.
On the other hand, cytokines including proinflammatory cytokines (IL-1, TNFα, IFN, IL-2, IL-6, IL-12) and consequently anti-inflammatory cytokines (IL-10, IL-11, IL-13, IL-1ra) are important players in the pathogenesis of autoimmune disease through multiple ways, such as regulating inflammation and angiogenesis [
40,
41].
It is interesting that in all the studied patients high levels of cytokines were recorded. Patients described in the current study showed high levels of IL-4, known to be involved in the development of autoantibodies and autoantibody mediated diseases [
42]. Even more important, IL-6 is a critical cytokine that mediates numerous inflammatory and immunomodulatory pathways. In this regard, dysregulated and persistent IL-6 production results in severe inflammatory and autoimmune disorders [
43]. An increase in cytokine with the key role in anti-inflammatory response, IL10, or of maintaining self-tolerance, IL2, was also demonstrated [
44,
45]. It might be suggested that the increase of inflammatory molecules levels with a state of chronic low-grade inflammation represents the underlying pathological mechanism leading to autoimmune diseases in this group of patients.
In conclusion, the results of the current study suggested a tendency to autoimmune phenomena as demonstrated by the finding of circulating autoantibodies, low levels of CD8 T cells and high levels of inflammatory cytokines. These evidences may be the first markers of the possible evolution to overt autoimmune disease.
Conclusion
Limited to tested patients with RASopaties, this study shows high prevalence of IgA deficiency, low TCD8 lymphocytes count and high inflammatory molecules levels. The detection of autoantibodies may anticipate the detection of overt autoimmune disease.
A comprehensive clinical and biochemical assessment should be carried out both at diagnosis and during the follow-up. We suggest the importance to include the dosage of serum immunoglobulins, and lymphocyte classes among the annual screening tests performed in this group of patients. The cytokine assay, on the other hand, could be more useful for research purposes. A correct endocrinological follow-up with thyroid profile is worthwhile, considering the high prevalence of positivity for autoantibodies.
In order to recommend routine screening for autoimmunity in patients with asymptomatic RASopathy, continuous monitoring will be required for possible emergence of autoimmune disease. Other studies are also needed to confirm our data.
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.